Archive for the ‘lack of IRB approval’ Category
Well, Boldt has another retraction, although he’d need to double his tally (which is in the range of 90) to match Fujii’s “impressive” haul.
The new paper is, well, old, having been published in 1996, some 14 years before Boldt’s tribulations began. The article was titled “Influence of different volume therapy regimens on regulators of the circulation in the critically ill.” It appeared in the British Journal of Anaesthesia, and has been cited 45 times, according to Thomson Scientific’s Web of Knowledge.
The article, in Heart, comes from a group of prominent researchers in Italy who have been arrested for possibly failing to adequately consent their patients, among other potential misdeeds.
According to Husten, the 2010 article in question, “A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up,” by Maria Grazia Modena (a past president of the Italian Society of Cardiology) and colleagues, may have been grossly misrepresented to the journal. Read the rest of this entry »
ORI, OHRP find “some human subject issues” in Henschke lung cancer studies, but no evidence of misconduct
We have an update on two papers about lung cancer screening by Claudia Henschke and colleagues that were subject to an Expression of Concern early last year.
The original Expression of Concern in Cancer read, in part: Read the rest of this entry »
Laurence Cole, an obstetrics researcher at the University of New Mexico, made an appearance on this blog in November 2011 after the American Journal of Obstetrics & Gynecology published a remarkably heavy-handed retraction of one of his papers.
Shortly after, we learned that the retraction was preceded by a strongly-worded letter from an attorney representing a company that had been miffed by the content of Cole’s article (the issue involved the effectiveness of commercially-available pregnancy tests, and Cole’s failure to adequately disclose a past relationship with the aggrieved company’s competitor). That letter read, in part: Read the rest of this entry »
A group of Turkish researchers has had a paper retracted on how to treat the bacterium that cause ulcers after the journal’s editors found “issues related to the institutional review board approval” of the project.
Here’s the notice for “Deservingness to state health services for South – South migrants: A preliminary study of Costa Rican providers’ views,” a paper in Social Science & Medicine by Kate Goldade and a colleague: Read the rest of this entry »
Keeping up with the various investigations into the activities of Yoshitaka Fujii — the assumed record holder for retractions by a single author, with 172 likely — can be a challenge. Between the journals pulling his papers and the institutions looking into his misconduct, it’s hard to keep everything straight.
But we have a new report, from a past employer, that makes for interesting reading and helps tie up some loose ends. The document is from Tsukuba University, where Fujii worked more than a decade ago when questions about the propriety of his findings first surfaced. Read the rest of this entry »
It was, as Nature News wrote last month, a story that “seemed too good to be true:”
Stem-cell transplant claims debunked
Transplant of induced pluripotent stem cells to treat heart failure probably never happened
Hisashi Moriguchi, a visiting researcher at the University of Tokyo, had claimed a result that would have put him years ahead of researchers toiling in stem cell research. But the claims were met with a great deal of doubt — to say the least — and the story began to unravel when Harvard, where Moriguchi said he’d done the work, denied it had ever taken place.
And as expected, the retractions have now started. Today, a Nature Publishing Group journal said they would be retracting two papers, “A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals” and “Successful cryopreservation of human ovarian cortex tissues using supercooling.” The notices for the Scientific Reports papers will both say the same thing: Read the rest of this entry »
PLOS ONE has retracted an article it published earlier this year by a group from Australia who failed to receive adequate ethics approval for their study.
The paper, “Late Complications of Clinical Clostridium Histolyticum Collagenase Use in Dupuytren’s Disease,” came from Warren M. Rozen, Yasith Edirisinghe and John Crock (sorry, irony machine not working today). Dupuytren’s causes thickening of the fascia in the hands and often requires surgery. In 2011 the FDA approved a treatment for the ailment that involves injections of an enzyme — Clostridium Histolyticum Collagenase, or CHC — into the affected area.
The Aussie article looked at the effects of CHC injections in 12 patients over one year, finding that two of the patients suffered Read the rest of this entry »